While reduced absenteeism and caregiver burden are important factors for employers, they don't resonate quite as much with payers. (Photo: Shutterstock)
When assessing the value of a new drug or medical treatment, insurance companies and other payers place a premium on efficacy, safety and cost.
Employers also care about whether adopting an innovation within their health care plan would result in reduced absenteeism and caregiver burden, as well as increased presenteeism and quality of life. However, payers place a low priority on such "indirect benefits," according to new study published in the Journal of Occupational and Environmental Medicine by researchers at the National Pharmaceutical Council and RTI Health Solutions.
Continue Reading for Free
Register and gain access to:
- Breaking benefits news and analysis, on-site and via our newsletters and custom alerts
- Educational webcasts, white papers, and ebooks from industry thought leaders
- Critical converage of the property casualty insurance and financial advisory markets on our other ALM sites, PropertyCasualty360 and ThinkAdvisor
Already have an account? Sign In Now
© 2024 ALM Global, LLC, All Rights Reserved. Request academic re-use from www.copyright.com. All other uses, submit a request to [email protected]. For more information visit Asset & Logo Licensing.
Katie Kuehner-Hebert
Katie Kuehner-Hebert is a freelance writer based in Running Springs, Calif. She has more than three decades of journalism experience, with particular expertise in employee benefits and other human resource topics.
